Qualigen Therapeutics (NASDAQ: OLGN) announced the presentation of three posters at the American Association of Cancer Research, New Orleans.
QN-302 could potentially treat pancreatic cancer
According to Michael Poirier, the CEO of Qualigen, the company’s top project involves QN-302. The company believes that this therapy could treat several types of tumours, which scientists use genomic quadruplexes to characterise.
Moreover, the posters indicated that the drug has significant anti-proliferative potency in vivo. These results applied to patients with metastatic prostate and pancreatic cancers. Poirier adds that the company intends to help people with cancer by creating the drug.
Pancreatic cancer is a severe illness that affects many people worldwide. Despite its severity, there is little treatment, and people with the disease often die quickly. Unfortunately, experts believe that the number of people with pancreatic cancer will go up.
The number of people who might die from the disease in 2022 is over 49,830 in the U.S alone. The number of people with pancreatic cancer could soon increase to 62,210. Physicians often give chemotherapy and targeted therapy to people with severe pancreatic cancer to lengthen their lifespan.
The drug could also treat prostate cancer
The company has found that the drug has significant activity in treating prostate cancer.
Furthermore, Qualigen discovered that the drug might be tolerated at therapeutic doses after conducting in vivo testing. They also discovered that QN-302 was more effective than abiraterone, commonly used to treat the disease.
Qualigen is a pharmaceutical company that focuses on creating therapies for pediatric and adult cancer. The company is working on QN-302, a molecule that binds to G4s. G4s are abundant in cancer-infected cells and reduce their proliferation.
The company is also working on QN-247, which inhibits the proliferation of cancer cells. This therapy works by inhibiting nucleolin which is also abundant in cancer-infected cells. The company has conducted preclinical studies on the drug and has found that it could treat acute myeloid leukaemia.
Qualigen doesn’t just deal with cancer treatments. It also operates a diagnostic branch. This sector of the company distributes and makes rapid blood testing kits and systems that are highly accurate and fast. They sell these tools to small hospitals and physician offices.
